Literature DB >> 26822424

EYE LENS DOSES IN NUCLEAR MEDICINE: A MULTICENTRIC STUDY IN BELGIUM AND POLAND.

Jérémie Dabin1, Renata Kopeć2, Lara Struelens3, Agnieszka Szumska2, Monika Tomaszuk4, Filip Vanhavere3.   

Abstract

This study aimed to investigate the level of the eye lens (EL) doses in nuclear medicine in the light of the new International Commission on Radiological Protection limit. In 7 Belgian and 1 Polish hospitals, 45 staff members were monitored for EL (Hp(3)) and whole-body (WB) (Hp(10)) doses using dedicated dosemeters. Weekly measurements were carried out and used to estimate annual doses. Mostly diagnostic procedures involving radionuclides such as (99m)Tc and (18)F were monitored; measurements were also performed for therapeutic procedures. The cumulative doses showed important variation across the participants. The weekly EL and WB doses ranged from 0.02 to 0.27 and 0.03 to 0.17 mSv, respectively; the annual EL and WB doses ranged from 0.6 to 9.3 and 0.9 to 8.0 mSv, respectively. Some correlation was found between the EL and the WB doses. No significant correlation with the manipulated activities was found.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26822424     DOI: 10.1093/rpd/ncv538

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  2 in total

1.  Cataract Risk in a Cohort of U.S. Radiologic Technologists Performing Nuclear Medicine Procedures.

Authors:  Marie-Odile Bernier; Neige Journy; Daphnee Villoing; Michele M Doody; Bruce H Alexander; Martha S Linet; Cari M Kitahara
Journal:  Radiology       Date:  2017-10-11       Impact factor: 11.105

2.  ESTIMATION OF HP(3) AMONG STAFF MEMBERS IN TWO NUCLEAR MEDICINE UNITS IN FINLAND.

Authors:  C Lindholm; A Pekkarinen; O Sipilä; A-L Manninen; M Lehtinen; T Siiskonen
Journal:  Radiat Prot Dosimetry       Date:  2020-08-28       Impact factor: 0.972

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.